Mr Brian Steven La Bella, LCSW | |
2626 Charles Dr, Chalmette, LA 70043-3779 | |
(504) 278-4006 | |
(504) 278-4007 |
Full Name | Mr Brian Steven La Bella |
---|---|
Gender | Male |
Speciality | Clinical Social Worker |
Experience | 33 Years |
Location | 2626 Charles Dr, Chalmette, Louisiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679617211 | NPI | - | NPPES |
000524967001 | Other | NY | BLUE CROSS OF WNY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 11696 (Louisiana) | Primary |
Entity Name | Hope Community Health Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1013579804 PECOS PAC ID: 5092128777 Enrollment ID: O20210120000610 |
News Archive
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.
Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology
Once, at the School of Nursing, grade point average and standardized test scores were all that mattered. Students hoped for the highest marks they could achieve and administrators used them as a barometer for success.
Researchers at Brigham and Women's Hospital (BWH) and colleagues have demonstrated for the first time in humans in a randomized clinical trial that low-dose aspirin - dosages equivalent to one baby aspirin (81 mg) - trigger the body to generate its own anti-inflammatory compounds that help fight unwanted inflammation.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Brian Steven La Bella, LCSW 5 Lyndell Ct, Chalmette, LA 70043-5306 Ph: (716) 886-5790 | Mr Brian Steven La Bella, LCSW 2626 Charles Dr, Chalmette, LA 70043-3779 Ph: (504) 278-4006 |
News Archive
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.
Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology
Once, at the School of Nursing, grade point average and standardized test scores were all that mattered. Students hoped for the highest marks they could achieve and administrators used them as a barometer for success.
Researchers at Brigham and Women's Hospital (BWH) and colleagues have demonstrated for the first time in humans in a randomized clinical trial that low-dose aspirin - dosages equivalent to one baby aspirin (81 mg) - trigger the body to generate its own anti-inflammatory compounds that help fight unwanted inflammation.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
› Verified 4 days ago
Katherine S Grieshaber, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1100 E Judge Perez Dr, Chalmette, LA 70043 Phone: 504-333-6988 | |
Jovel Finney, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3101 Jean Lafitte Pkwy, Suite A, Chalmette, LA 70043 Phone: 504-610-0477 | |
Nicole Crowden, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 908 W Judge Perez Dr, Suite D, Chalmette, LA 70043 Phone: 504-715-1856 Fax: 504-210-0527 | |
Ms. Sharon James Sanders, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8101 W Judge Perez Dr, Bldg. B, Chalmette, LA 70043 Phone: 504-278-7401 Fax: 504-278-7475 | |
Cornelia Cager Bonds, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2626 Charles Dr, Chalmette, LA 70043 Phone: 504-278-4006 Fax: 504-278-4007 | |
Ms. Nicole Renee Meredith, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 8050 W Judge Perez Dr Ste 1300, Chalmette, LA 70043 Phone: 504-575-3712 | |
Mrs. Rachel Hetler Penn, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2626 Charles Dr, Chalmette, LA 70043 Phone: 504-278-4006 Fax: 504-278-4007 |